AbbVie completes acquisition of Cerevel Therapeutics
by
Contributor since / Followers
Contributor since / Followers
4 months ago
Michael Vi/iStock Editorial via Getty Images
- AbbVie (NYSE:ABBV) has completed its ~$8.7B ($45 per share) acquisition of Cerevel Therapeutics, giving it access to a pipeline of neurological disease assets.
- Cerevel’s latest stage asset, in phase 3, is tavapadon for Parkinson’s disease. In phase 2, the company has emraclidine for schizophrenia (also in phase 1 Alzheimer’s disease psychosis), darigabat for epilepsy and panic disorder, and CVL-871 for dementia-related apathy
- AbbVie also reaffirmed its 2024 full-year adjusted diluted EPS guidance of $10.71-$10.91. Consensus is $10.88.